AGEN
AgenusAGEN
AGEN
About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Employees: 389
0
Funds holding %
of 6,794 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
762% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $1.3M
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
10% more funds holding
Funds holding: 88 [Q2] → 97 (+9) [Q3]
8% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 24
4.66% less ownership
Funds ownership: 43.62% [Q2] → 38.96% (-4.66%) [Q3]
94% less capital invested
Capital invested by funds: $822M [Q2] → $45.7M (-$777M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
96%
upside
Avg. target
$7
96%
upside
High target
$7
96%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 23% 1-year accuracy 20 / 86 met price target | 96%upside $7 | Neutral Reiterated | 29 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 23% 1-year accuracy 20 / 86 met price target | 96%upside $7 | Neutral Maintained | 12 Nov 2024 |
Financial journalist opinion
Based on 8 articles about AGEN published over the past 30 days
Neutral
Business Wire
3 days ago
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiative follows the successful closing of a $22 million mortgage secured by key real estate assets, providing the compan.
Neutral
Business Wire
1 week ago
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville, California. Facilitated by L&L Capital, the transaction yields $20 million in net proceeds after closing costs and interest reserve, bolstering the company's cash p.
Negative
Zacks Investment Research
2 weeks ago
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Agenus (AGEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Negative
Zacks Investment Research
2 weeks ago
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
3 weeks ago
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neutral
Seeking Alpha
3 weeks ago
Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Garo Armen - Chairman and CEO Steven O'Day - CMO Robin Taylor - CCO Christine Klaskin - VP of Finance Conference Call Participants Emily Bodnar - H.C. Wainright Madeline Stone - William Blair Operator Good morning and welcome to Agenus' Third Quarter 2024 Conference Call and Webcast.
Negative
Zacks Investment Research
3 weeks ago
Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $2.10. This compares to loss of $3.20 per share a year ago.
Neutral
Business Wire
3 weeks ago
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. “BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short,” said Garo Armen, Ph.D., Chairman and CEO of Agenus. “Its potential extends bey.
Neutral
Business Wire
1 month ago
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D.,.
Neutral
Accesswire
1 month ago
November 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AGEN
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110801&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™